Bicycle Therapeutics PLC Sponsored ADR
BCYC Healthcare Biotechnology
Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024. In the quarter to June 2026, revenue fell 78.5%, EPS grew 36.8% and free cash flow grew 32.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow BCYC
Bicycle Therapeutics PLC Sponsored ADR (BCYC) EV/Sales
As of 16 October 2026, Bicycle Therapeutics PLC Sponsored ADR (BCYC) trades at a EV/Sales of −4.0×. Over the past ten years it has ranged from −12.8× (April 2025) to 111× (November 2021); the current reading is higher than 15% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.6× | — |
| FY2024 | −1.3× | — |
| FY2023 | 6.1× | (84.83%) |
| FY2022 | 40.4× | (57.79%) |
| FY2021 | 95.7× | 345.70% |
| FY2020 | 21.5× | 2,027.01% |
| FY2019 | 1.0× | — |
| FY2018 | −4.6× | — |
| FY2017 | −4.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −3.2× | — |
| Mar 2026 | −3.4× | — |
| Dec 2025 | −1.6× | — |
| Sep 2025 | −3.2× | — |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −35.1× |
| TRDA Entrada Therapeutics, Inc. compare | −8.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 29.0× |
| YARW Yarrow Bioscience, Inc compare | 124× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)